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Introduction
This clinical case refers to an 83-year-old man with moder-
ate chronic obstructive pulmonary disease and shows that
implementation of appropriate medical therapy according
to the European Society of Cardiology/Heart Failure
Association (ESC/HFA) guidelines improves symptoms and
quality of life.1 The case also illustrates that optimization
of glucose metabolism with a more lenient glucose control
was most probably important in improving the overall clini-
cal status and functional capacity.
Case presentation
The patient has family history of coronary artery disease as
his brother had suffered an acute myocardial infarction
(AMI) at the age of 64 and his sister had received coronary
artery by-pass. He also has a 14-year diagnosis of arterial
hypertension, and he is diabetic on oral glucose-lowering
agents since 12years. He smokes 30 cigarettes per day
since childhood.
In February 2009, after 2 weeks of angina for moderate
efforts, he suffered an acute anterior myocardial infarc-
tion. He presented late (after 14h since symptom onset) at
the hospital where he had been treated conservatively and
had been discharged on medical therapy: Atenolol 50mg
o.d., Amlodipine 2.5mg o.d., Aspirin 100mg o.d.,
Atorvastatin 20mg o.d., Metformin 500mg tds, Gliclazide
30mg o.d., Salmeterol 50, and Fluticasone 500mg oral
inhalers.
Four weeks after discharge, he underwent a planned
electrocardiogram (ECG) stress test that documented si-
lent effort-induced ST-segment depression (1.5mm in V4–
V6) at 50W.
He underwent a coronary angiography (June 2009) and
left ventriculography that showed a not dilated left ventri-
cle with apical dyskinesia, normal left ventricular ejection
fraction (LVEF, 52%); occlusion of proximal LAD, 60% steno-
sis of circumflex (CX), and 60% stenosis of distal right coro-
nary artery (RCA). An attempt to cross the occluded left
anterior descending (LAD) was unsuccessful.
He was therefore discharged on medical therapy with:
Atenolol 50mg o.d., Atorvastatin 20mg o.d., Amlodipine
2.5mg o.d., Perindopril 4mg o.d., oral isosorbide mono-
nitrate (ISMN) 60mg o.d., Aspirin 100mg o.d., metformin
850mg tds, Gliclazide 30mg o.d., Salmeterol 50mcg, and
Fluticasone 500mcg b.i.d. oral inhalers.
He had been well for a few months but in March 2010 he
started to complain of retrosternal constriction associated
to dyspnoea for moderate efforts (New York Heart
Association (NYHA) II–III, Canadian Class II).
Learning points
• Patients with ischaemic heart disease that develop
heart failure should be treated as per appropriate
European Society of Cardiology/Heart Failure
Association (ESC/HFA) guidelines.
• Glucose control in diabetic patients with heart fail-
ure should be more lenient that in patients with-
out cardiovascular disease.
• Optimization of cardiac metabolism and control of
heart rate should be a priority for the treatment of
angina in patients with heart failure of ischaemic
origin.
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For this reason, he was prescribed a second coronary an-
giography that showed progression of atherosclerosis with
80% stenosis on the circumflex (after the I obtuse marginal
branch) and distal RCA. The LADwas still occluded.
After consultation with the heart team, CABG was
avoided because surgical the risk was deemed too high and
the patient underwent palliative percutaneous coronary
intervention (PCI) of CX and RCA. It was again attempted to
cross the occlusion on the LAD. But this attempt was,
again, unsuccessful. Collateral circulation from posterior
interventricular artery (PDL) to the LAD was found. The
pre-PCI echocardiogram documented moderate left ven-
tricular dysfunction (EF 38%), the pre-discharge echocar-
diogram documented a LVEF of 34%. Because of the
reduced LVEF, atenolol was changed for Bisoprolol (5mg
o.d.).
At follow-up visit in December 2012, the clinical status
and the haemodynamic conditions had deteriorated. He
complained of worsening effort-induced dyspnoea/angina
that now occurred for less than a flight of stairs (NYHA III).
On clinical examination clear signs of worsening heart
failure were detected (Table 1). His medical therapy
was modified to: Bisoprolol 5mg o.d., Atorvastatin 20mg
o.d., Amlodipine 2.5mg o.d., Perindopil 5mg o.d., ISMN
60mg o.d., Aspirin 100mg o.d., Metformin 500mg tds,
Furosemide 50mg o.d., Gliclazide 30mg o.d., Salmeterol
50mcg oral inhaler, and Fluticasone 500mcg oral inhaler. A
stress perfusion cardiac scintigraphy was requested and
revealed dilated ventricles with LVEF 19%, fixed apical
perfusion defect and reversible perfusion defect of the
antero-septal wall (ischaemic burden <10%, Figure 1). He
was admitted, and an ICD was implanted.
In March 2013, he felt slightly better but still complained
of effort-induced dyspnoea/angina (NYHA III, Table 1).
Medical therapy was updated with bisoprolol changed with
Nebivolol 5mg o.d. and perindopril changed to Enalapril
10mg b.i.d. The switch from bisoprolol to nebivolol was un-
dertaken because of the better tolerability and outcome
data with nebivolol in elderly patients with heart failure.
Perindopril was switched to enalapril because the first one
has no indication for the treatment of heart failure.
In September 2013, the clinical conditions were
unchanged, he still complained of effort-induced dys-
pnoea/angina (NYHA III) and did not notice any change in
his exercise capacity. His BNP was 1670. He was referred
for a 3-month cycle of cardiac rehabilitation during which
his medical therapy was changed to: Nebivolol 5mg o.d.,
Ivabradine 5mg b.i.d., uptitrated in October to 7.5 b.i.d.,
Trimetazidine 20mg tds, Furosemide 50mg, Metolazone
5mg o.d., K-canrenoate 50mg, Enalapril 10mg b.i.d.,
Clopidogrel 75mg o.d., Atorvastatin 40mg o.d., Metformin
500mg b.i.d., Salmeterol 50mcg oral inhaler, and
Fluticasone 500mcg oral inhaler.
At the follow-up visit in January 2014, he felt much bet-
ter and had symptomatically, he no longer complained of
angina, nor dyspnoea (NYHA Class II, Table 1).
Trimetazidine was added because of its benefits in heart
failure patients of ischaemic origin and because of its
Table 1 Clinical parameters during follow-up visits
December 2012 March 2013 September 2013 January 2014 January 2015
Weight (kg) 72 71 74 70 68
Height (cm) 170 170 170 170 170
BMI 24.9 24.9 25.1 24.9 24.8
JVP þ2 cm H2O þ2 cm H2O þ2 cm H2O Normal Normal
Oedema Bilateral oedema up
to mid shins
Bilateral pretibial
oedema (2þ)
Bilateral pretibial
oedema (3þ)
No pedal
oedema
No pedal
oedema
Blood pressure (mmHg) 115/80 115/75 110/60 110/70 112/68
Pulse (bpm) 88 86 92 68 56
Auscultation
Heart Systolic murmur 4/6
at apex, III sound
Systolic murmur 4/6
at apex, III sound
Systolic murmur 4/6
at apex, III sound
Systolic murmur
4/6 at apex
Systolic murmur
4/6 at apex
Lungs Bilateral ﬁne basilar
crackles
Bilateral ﬁne basilar
crackles
Bilateral ﬁne basilar
and mid lung
crackles
Clear Clear
Laboratory ﬁndings
FPG (mg/dL) 100 98 96 106 112
HbA1c (%) 6.8 6.7 6.6 7 7.3
Plasma creatinine (mg/dL) 1.1 1.2 1.5 1.1 1.2
Triglycerides 118 mg/dL NA NA 107 mg/dL 114 mg/dL
Total cholesterol 146 mg/dL NA NA 142 mg/dL 148 mg/dL
LDL-C 68 mg/dL NA NA 64 mg/dL 68 mg/dL
HDL-C 51 mg/dL NA NA 48 mg/dL 54 mg/dL
BNP NA 862 1670 276 244
LVEF 19 20 32 32
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effect on functional capacity. Ivabradine was added to re-
duce heart rate since it was felt that increasing nebivolol,
that was already titrated to an effective dose, would have
had led to hypotension.
He missed his follow-up visits in June and October
2014 because he was feeling well and he had decided to
spend some time at his house in the south of Italy. In
January and June 2015, he was well, asymptomatic
(NYHA I–II) and able to attend his daily activities. He did
not complain of angina nor dyspnoea and reported no
limitations in his daily activities. Unfortunately, in
November 2015 he was hit by a moped while on the ze-
bra crossing in Rome and he later died in hospital as a
consequence of the trauma.
Discussion
This case highlights the need of optimizing both the
heart failure and the anti-anginal medications in
patients with heart failure of ischaemic origin. This pa-
tient has improved dramatically after the up-titration of
diuretics, the control of heart rate with nebivolol and
ivabradine and the additional use of trimetazidine.1–3 All
these drugs have contributed to improve the clinical sta-
tus together with a more lenient control of glucose me-
tabolism.4 This is another crucial point to take into
account in diabetic patients, especially if elderly, with
heart failure in whom aggressive glucose control is detri-
mental for their functional capacity and long-term
prognosis.5
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Figure 1 Myocardial perfusion scintigraphy and left ventriculography showing dilated left ventricle with left ventricular ejection fraction 19%.
Reversible perfusion defects on the antero-septal wall and ﬁxed apical perfusion defect.
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